144. レノックス・ガストー症候群
［臨床試験数：80，薬物数：63（DrugBank：11），標的遺伝子数：49，標的パスウェイ数：59］
Searched query = "Lennox-Gastaut syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-004350-82-BG (EUCTR) | 10/11/2008 | 13/11/2008 | Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox Gastaut Syndrome - | Lennox-Gastaut syndrome MedDRA version: 9.1;Level: LLT;Classification code 10048816;Term: Lennox-Gastaut syndrome | Trade Name: Clobazam Product Name: Clobazam Tablets Product Code: Clobazam Tablets 5mg INN or Proposed INN: CLOBAZAM Other descriptive name: Clobazam PhEur Trade Name: Clobazam Product Name: Clobazam Tablets Product Code: Clobazam Tablets 10mg INN or Proposed INN: Clobazam Other descriptive name: Clobazam PhEur Trade Name: Clobazam Product Name: Clobazam Tablets Product Code: Clobazam Tablets 20mg INN or Proposed INN: Clobazam Other descriptive name: Clobazam Pheur | Ovation Pharmaceuticals | NULL | Not Recruiting | Female: yes Male: yes | 304 | Bulgaria;Lithuania | ||||
| 2 | EUCTR2007-004322-24-BG (EUCTR) | 28/10/2008 | 03/11/2008 | Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome. | Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome. | Lennox-Gastaut Syndrome MedDRA version: 9.1;Level: LLT;Classification code 10048816;Term: Lennox-Gastaut syndrome | Trade Name: Clobazam Product Name: Clobazam Tablets 5mg INN or Proposed INN: Clobazam Other descriptive name: Clobazam PhEur | Ovation Pharmaceuticals Inc. | NULL | Not Recruiting | Female: yes Male: yes | 240 | Bulgaria;Lithuania | |||
| 3 | EUCTR2007-004322-24-LT (EUCTR) | 17/03/2008 | 21/01/2008 | Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome. | Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome. | Lennox-Gastaut Syndrome MedDRA version: 9.1;Level: LLT;Classification code 10048816;Term: Lennox-Gastaut syndrome | Trade Name: Clobazam Product Name: Clobazam Tablets 5mg INN or Proposed INN: Clobazam Other descriptive name: Clobazam PhEur | Lundbeck Inc | NULL | Not Recruiting | Female: yes Male: yes | 240 | Bulgaria;Lithuania | |||
| 4 | EUCTR2007-004350-82-LT (EUCTR) | 17/03/2008 | 21/01/2008 | Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox Gastaut Syndrome - | Lennox-Gastaut syndrome MedDRA version: 9.1;Level: LLT;Classification code 10048816;Term: Lennox-Gastaut syndrome | Trade Name: Clobazam Product Name: Clobazam Tablets Product Code: Clobazam Tablets 5mg INN or Proposed INN: CLOBAZAM Other descriptive name: Clobazam PhEur Trade Name: Clobazam Product Name: Clobazam Tablets Product Code: Clobazam Tablets 10mg INN or Proposed INN: Clobazam Other descriptive name: Clobazam PhEur Trade Name: Clobazam Product Name: Clobazam Tablets Product Code: Clobazam Tablets 20mg INN or Proposed INN: Clobazam Other descriptive name: Clobazam Pheur | Lundbeck Inc | NULL | Not Recruiting | Female: yes Male: yes | 304 | Bulgaria;Lithuania | ||||
| 5 | NCT00518713 (ClinicalTrials.gov) | August 2007 | 20/8/2007 | Clobazam in Patients With Lennox-Gastaut Syndrome | Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut Syndrome | Epilepsy;Epilepsy, Generalized;Seizures | Drug: Clobazam Low Dose;Drug: Clobazam Medium Dose;Drug: Clobazam High Dose;Drug: Placebo | Lundbeck LLC | NULL | Completed | 2 Years | 60 Years | All | 238 | Phase 3 | United States;Australia;Belarus;India;Lithuania;Serbia |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT01160770 (ClinicalTrials.gov) | December 2005 | 18/6/2010 | Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome | Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome | Lennox-Gastaut Syndrome | Drug: Clobazam | Lundbeck LLC | NULL | Completed | 2 Years | 60 Years | All | 267 | Phase 3 | NULL |
| 7 | NCT00162981 (ClinicalTrials.gov) | October 2005 | 9/9/2005 | Clobazam in Subjects With Lennox-Gastaut Syndrome | Safety and Efficacy of Clobazam in Subjects With Lennox-Gastaut Syndrome | Epilepsy;Epilepsy, Generalized;Seizures | Drug: Clobazam Low Dose;Drug: Clobazam High Dose | Lundbeck LLC | NULL | Completed | 2 Years | 30 Years | All | 68 | Phase 2 | United States |